Quick Answer
Anika Therapeutics, Inc. reported Research And Development Expense of $25.77 million for the year ending 2025.
- Anika Therapeutics, Inc. showed an increase of +0.9% in Research And Development Expense from 2024 to 2025.
- This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Anika Therapeutics, Inc.'s Research And Development Expense has grown by 215.0%.
- Historical annual values: Fiscal year 2025: $25.77 million | Fiscal year 2024: $25.54 million | Fiscal year 2023: $21.76 million | Fiscal year 2022: $18.32 million | Fiscal year 2021: $27.33 million | Fiscal year 2020: $23.43 million | Fiscal year 2019: $16.67 million | Fiscal year 2018: $18.19 million | Fiscal year 2017: $18.79 million | Fiscal year 2016: $10.73 million | Fiscal year 2015: $8.99 million | Fiscal year 2014: $8.14 million | Fiscal year 2013: $7.06 million | Fiscal year 2012: $5.39 million | Fiscal year 2011: $6.17 million | Fiscal year 2010: $6.87 million | Fiscal year 2009: $8.18 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: